Read More

Psyence inks several deals to expand psilocybin research, footprint

Psyence Biomedical Ltd (Nasdaq: PBM) is poised to hit several psilocybin-related “milestones” in coming months, including the acquisition of drug developer Clairvoyant, the launch of research into psilocybin as a treatment for substance use disorders and ongoing clinical trials in Australia for psilocybin in treating adjustment disorder. CEO Dr. Neil …